(Q39217214)

10 September 2017

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer (English)

1 reference

10 September 2017

1 reference

Virginie Westeel

1

1 reference

10 September 2017

Elisabeth Quoix

2

1 reference

10 September 2017

Denis Moro-Sibilot

3

1 reference

10 September 2017

Mariette Mercier

4

1 reference

10 September 2017

Jean-Luc Breton

5

1 reference

10 September 2017

Didier Debieuvre

6

1 reference

10 September 2017

Philippe Richard

7

1 reference

10 September 2017

Mary-Anne Haller

8

1 reference

10 September 2017

Bernard Milleron

9

1 reference

10 September 2017

Dominique Herman

10

1 reference

10 September 2017

Marie-Claude Level

11

1 reference

10 September 2017

François-Xavier Lebas

12

1 reference

10 September 2017

Marc Puyraveau

13

1 reference

10 September 2017

Alain Depierre

14

1 reference

10 September 2017

French Thoracic Oncology Collaborative Group (GCOT)

15

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Journal of the National Cancer Institute

10 September 2017

1 reference

10 September 2017

97

1 reference

10 September 2017

7

1 reference

10 September 2017

499-506

1 reference

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

10 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI096

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJI096

1 reference

10 September 2017

1 reference